JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.

IκK/IκB

IκK/IκB inhibitors act on the IκB kinase (IKK) complex, which frees nuclear factor kappa B (NF-κB) from IκB. In 1997 a cytokine-responsive IKK was purified, and the complex was shown to contain two catalytic subunits, IKKα and IKKβ. The kinases phosphorylate IκBα, which marks this inhibitor for degradation and frees NF-κB dimers to enter the nucleus. BMS-345541 HCl, described in 2003, binds an allosteric site on IKK and blocks NF-κB-dependent transcription. IKK-16 inhibits IKKβ and the IKK complex, while IMD 0354 and Bay 65-1942 HCl act mainly on IKKβ. BAY 11-7085 is used to block IκBα phosphorylation in cells. BX-795 targets the related TANK-binding kinase 1 (TBK1) and IKKε along with 3-phosphoinositide-dependent protein kinase 1 (PDK1).

Cat. No.

A11324

CAS No.

218600-44-3

Bardoxolone (CDDO)

Synonyms: RTA 401; CDDO

Bardoxolone methyl, previously known as RTA 402, is the lead molecule in Reata's portfolio of Antioxidant Inflammation Modulators (AIMs).

In stock View Details

5 mg

$60.00

10 mg

$85.00

All 6 sizes

IκK/IκB

Bardoxolone (CDDO)